The Plasminogen pipeline drugs market research report outlays comprehensive information on the Plasminogen targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Plasminogen pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Hematological Disorders, Dermatology, and Genetic Disorders which include the indications Acute Ischemic Stroke, Myocardial Infarction, Bleeding And Clotting Disorders, Hemophilia A (Factor VIII Deficiency), Diabetic Foot Ulcers, and Congenital Plasminogen Deficiency. It also reviews key players involved in Plasminogen targeted therapeutics development with respective active and dormant or discontinued products.
The Plasminogen pipeline targets constitutes close to 22 molecules. Out of which, approximately 21 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 4, 3, 2, 1, 5, and 4 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Plasminogen overview
Plasminogen dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, it weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases, and several complement zymogens such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis.
For a complete picture of Plasminogen’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
